Pulmonary Arterial Hypertension: Diagnostic Workup and Initial Treatment
Right heart catheterization is mandatory to confirm the diagnosis of pulmonary arterial hypertension, and treatment-naïve patients at low or intermediate risk should receive initial oral combination therapy with drugs from different pathways, while high-risk patients require upfront triple therapy including a parenteral agent. 1
Diagnostic Workup Algorithm
Initial Screening and Clinical Assessment
When PAH is suspected (progressive exertional dyspnea, unexplained fatigue, syncope, or chest discomfort—particularly in patients with connective tissue disease, HIV, portal hypertension, or family history), begin with:
- Transthoracic echocardiography as the primary screening tool to estimate pulmonary artery pressures and assess right ventricular structure/function 2
- ECG, chest radiography, and BNP/NT-proBNP measurement
- Pulmonary function testing with DLCO and arterial blood gas analysis
- Ventilation-perfusion (V/Q) scanning to exclude chronic thromboembolic pulmonary hypertension (CTEPH)—a normal V/Q scan effectively rules out CTEPH 2
Critical pitfall: Do not use CT or MRI alone to exclude CTEPH; V/Q scanning is required 2. If V/Q suggests CTEPH, pulmonary angiography is mandatory for anatomic definition.
Confirmatory Testing
- Right heart catheterization (RHC) is the only way to definitively diagnose PAH and must be performed before initiating PAH-specific therapy 1
- RHC confirms hemodynamic criteria: mean pulmonary artery pressure ≥25 mmHg, pulmonary arterial wedge pressure ≤15 mmHg, elevated pulmonary vascular resistance
- Vasoreactivity testing during RHC using short-acting agents (IV epoprostenol, adenosine, or inhaled nitric oxide) is required in idiopathic PAH (IPAH), heritable PAH (HPAH), and drug-induced PAH to identify calcium channel blocker responders 1
Additional Workup
- Testing for connective tissue disease and HIV infection in all unexplained PAH cases 2
- 6-minute walk distance (6MWD) for functional assessment
- Comprehensive risk stratification using clinical assessment, exercise tests, biochemical markers, echocardiographic and hemodynamic parameters 1
Initial Treatment Strategy
Risk-Based Treatment Approach
For vasoreactive patients (positive acute vasoreactivity test defined as fall in mean PAH ≥10 mmHg to ≤40 mmHg with increased or unchanged cardiac output):
- High-dose calcium channel blockers are the treatment of choice 1
- Do not use calcium channel blockers empirically without documented vasoreactivity—this can be harmful 2
For non-vasoreactive patients at low or intermediate risk:
- Initial oral combination therapy is recommended using approved drugs from different pathways (endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators) 1
- Monotherapy is also acceptable in this population but combination therapy is increasingly preferred 1
For high-risk patients:
- Upfront triple combination therapy including a parenteral prostacyclin analog is the standard of care 3
Treatment Goals
Target a low-risk status with the following specific benchmarks:
- WHO Functional Class I or II
- 6-minute walk distance >440 meters (adjust for age and comorbidities—lower acceptable in elderly, higher needed in young healthy patients) 4
- Near-normal BNP/NT-proBNP levels
- Preserved right ventricular function on imaging
Essential General Measures
- Pregnancy must be avoided—this is a Class I recommendation due to high maternal mortality risk 1, 4
- Immunization against influenza and pneumococcal infection 4
- Psychosocial support 4
- Supervised exercise training in physically deconditioned patients already on medical therapy 4
- Oxygen supplementation for WHO-FC III-IV or PaO2 <60 mmHg
- Diuretics for right heart failure management
Critical Management Principles
Do not initiate PAH-specific therapy empirically—diagnosis must be confirmed by RHC at an expert center 5. The 2015 ESC/ERS guidelines emphasize that all PAH patients should be managed at specialized referral centers with multidisciplinary teams including cardiology and pulmonary medicine physicians, clinical nurse specialists, radiologists, and access to psychological/social support 1.
Avoid PAH-specific therapies in pulmonary hypertension due to left heart disease or lung diseases—these are not indicated and may be harmful 1.
Follow-up Strategy
Reassess every 3-6 months in stable patients using the same multidimensional risk assessment tools 1. If inadequate response to initial therapy, escalate to sequential combination therapy by adding agents from different pathways or switching within pathways based on clinical trial evidence 1.
Lung transplantation remains an option for patients with inadequate response to maximal medical therapy 6.